InnFocus reaches its goal of enrolling 75 patients in a Phase I clinical study for its MicroShunt glaucoma eye-drainage implant.
InnFocus has reached its goal of enrolling 75 patients in a Phase I clinical study for its MicroShunt glaucoma eye-drainage implant.
The device is used to help reduce pressure within the eye in patients with glaucoma. The product is intended to be an alternative to traditional glaucoma surgery.
from MassDevice - FDA and Medical device business news and jobs for the medical device industry http://ift.tt/1OnPOHY
Cap comentari:
Publica un comentari a l'entrada